Loading...
Market
Story
Genentech Acquires Regor's CDK Inhibitors in Definitive Purchase Agreement for $850 Million
Sep 30, 2024, 08:46 AM
Genentech has announced the acquisition of Regor's portfolio of next-generation CDK inhibitors for $850 million upfront, with potential for additional milestone payments. The definitive purchase agreement aims to enhance Genentech's capabilities in the treatment of breast cancer.
View original story
Similar markets
Yes • 50%
No • 50%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
Yes • 50%
No • 50%
Breakthrough Therapy • 25%
Fast Track • 25%
Orphan Drug • 25%
None • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other Cancer Type • 25%
